Everything documented about cagrilintide dosing comes from clinical trial protocols, not an approved product label, because no regulator has cleared it for general use with an official prescribed dose. Across those trials the drug is described as a once-weekly subcutaneous injection that starts low and is titrated upward over several weeks toward a maintenance dose, an approach the literature ties to limiting the gastrointestinal effects that follow an abrupt high dose.
Cagrilintide's dosing is documented only from clinical trial protocols, which describe a once-weekly subcutaneous injection titrated gradually toward a maintenance dose, with no regulator-approved label defining an official dose.
Across its clinical program cagrilintide has been given as a subcutaneous injection once per week, a schedule made possible by deliberate molecular engineering. As an acylated amylin analogue, it binds albumin in the blood through a fatty-acid modification that slows clearance and holds a therapeutic level for roughly a week from a single dose. That marks a sharp departure from earlier amylin therapy such as pramlintide, which required several injections a day before meals.
Clinical trials have administered cagrilintide as a once-weekly subcutaneous injection, a weekly interval enabled by a fatty-acid modification that binds albumin and sustains drug levels for about seven days.
Trial procedures describe the injection going into subcutaneous fat at the same sites familiar from other weekly injectables: the abdomen away from the navel, the front or outer thigh, and the back of the upper arm. For a long-acting albumin-binding peptide the specific region has only a minor effect on absorption, so trial guidance emphasizes rotation and consistent technique over any single ideal spot.
Trial protocols place the subcutaneous injection in the abdomen, thigh, or upper arm and rotate the site each week, because for an albumin-binding peptide the region chosen has only a minor effect on absorption while repeated single-site use risks lipohypertrophy.
The dose is raised in steps because cagrilintide's most common and most limiting effects are gastrointestinal: nausea, vomiting, and appetite reduction severe enough to cause discomfort. These effects hit hardest when the body first meets a given dose and fade as tolerance builds, so a gradual ramp gives the gut time to adapt at each level, and it keeps people from abandoning treatment over an abrupt wave of nausea.
Cagrilintide is titrated over several weeks from a low starting dose to a target maintenance dose because introducing the full dose at once provokes intense nausea and vomiting that drives people off therapy, the same start-low-go-slow logic used with GLP-1 receptor agonists.
Cagrilintide has been tested across a spread of weekly maintenance doses rather than one fixed strength, because dose-finding was a central goal of the early and mid-stage program. The consistent signal is dose-dependent: higher weekly doses produced greater appetite suppression and weight loss on average, though the top of the range also carried more frequent and more intense gastrointestinal effects.
Cagrilintide's trials compared multiple weekly maintenance doses against placebo and found a dose-dependent response, where higher doses produced greater weight loss but also more gastrointestinal side effects, so dose-finding aimed at the level where added benefit still justified the added tolerability cost.
CagriSema is the trial combination that pairs cagrilintide with the GLP-1 receptor agonist semaglutide in a single weekly subcutaneous product. Because both agents suppress appetite through different but reinforcing pathways and both cause the same family of gastrointestinal effects, the two are titrated together on one coordinated schedule rather than on separate timelines.
| Criteria | Cagrilintide alone | CagriSema combination |
|---|---|---|
| Components | Amylin analogue only | Cagrilintide plus semaglutide |
| Titration | Single agent stepped up weekly | Both agents stepped up together on one schedule |
| Weight loss in trials | Meaningful on its own | Greater than either component alone |
| GI side-effect handling | One appetite-acting drug | Fixed ratio managing additive nausea |
In the CagriSema combination, cagrilintide and semaglutide are titrated together on one coordinated weekly schedule toward a shared maintenance level, which keeps the two exposures in a consistent ratio and produced greater trial weight loss than either agent alone.
Cagrilintide reduces hunger only while it is circulating, so its effect is reversible: once dosing stops and the drug clears, the appetite-suppressing signal fades, hunger climbs back toward its pre-treatment level, and much of the lost weight tends to return over the following weeks and months. That pattern frames the drug as a chronic therapy meant for ongoing use rather than a short course that produces a permanent change.
Cagrilintide's appetite suppression lasts only while the drug is present, so discontinuation is followed by returning hunger and regain of much of the lost weight, the same reversibility seen across GLP-1 based weight medicines that marks the class as chronic therapy.
Cagrilintide is investigational, still under study and not approved by any regulator as a standalone product, and without approval there is no official label to fix an authorized dose, indication, or schedule. An approved label is the output of a full regulatory review, where an agency weighs the complete trial evidence and then sets the specific dose, patient population, warnings, and administration instructions.
Because cagrilintide is investigational and carries no approved label, the only dosing figures that exist are those set by individual trial protocols to characterize the drug in controlled research, not an authorized regimen for general use.
Supervision matters because cagrilintide stacks three factors that each call for professional oversight on their own: an active appetite-altering effect, an escalating dose schedule, and an unapproved investigational status. During titration a clinician tracks how each dose step is tolerated, judges whether the next increase fits or should wait, and manages the nausea, vomiting, and reduced intake that can accompany a rise in dose.
Cagrilintide's dosing is described in terms of what trials do rather than as a self-administration guide because its active appetite effect, escalating dose schedule, and investigational status each require continuous clinical judgment to keep the benefit-versus-side-effect balance safe.
Educational use only. This article describes what the published scientific and clinical literature reports about Cagrilintide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
